Poster Session

P3–006 GDP CHEMOTHERAPY FOR RELAPSED/REFRACTORY LYMPHOMAS IS EFFECTIVE AND SAFE

A. Ouchi1, M. Yokoyama1, K. Takeuchi2, H. Nitta1, K. Ueda1, N. Nishimura1, N. Tsuyama2, Y. Terui1, K. Hatake1
1Hematology Oncology, Cancer Institute Hospital, 2Pathology, Cancer Institute, Japanese Foundation for Cancer Research

Introduction: Gemcitabine, dexamethasone, cisplatin (GDP) therapy is a new salvage therapy for lymphomas in Japan, approved by Ministry of Health, Labour and Welfare in September 2012. At American Society of Hematology annual meeting in 2012, GDP was revealed not to be inferior to dexamethasone, cytarabine, cisplatin (DHAP) therapy, which is another standard salvage therapy, at the response rate, 4 years overall survival and event free survival. Our department started GDP therapy for relapsed/refractory lymphomas patients (pts.) in November 2012, and has experienced six cases until February 2013. We report the efficacy and safety of GDP.

Methods: We reviewed six relapsed/refractory lymphomas pts. treated with GDP to assess the efficacy and severe adverse event (SAE). All the histopathology samples were reviewed by expert hematopathologists, according to the WHO classification.

Results: The baseline pts. characteristics included three male, three female, median age was 68.74(20.4-79.5), two pts. with diffuse large B cell lymphoma (DLBCL), in which one had CD5 + DLBCL, one with mediastinal large B cell lymphoma, one with Hodgkin Lymphoma, one with mantle cell lymphoma, and one with follicular lymphoma. The median number of regimens prior to GDP was 2.5(2-6). At the time of GDP, two pts. had stage II(according to Ann Arbor staging system), two pts. had stage III, and two pts. had stage IV. One pts. (16.7%) has achieved partial response, one pt. (16.7%) had stable disease, three pts. (50%) had progression disease, and one was unevaluable. One pt. achieved PR has proceeded peripheral blood stem cell collection after three cycles of GDP. About SAEs, 3 pts. had grade 3/4 thrombocytopenia, 2 pts. had grade 3/4 neutropenia, 2 pts had grade 3/4 anemia, and 1 pt. had grade 3/4 AST and ALT increased on the first cycle of GDP. There was no treatment-related death.

Conclusions: GDP therapy is effective and safe. Grade 4 thrombocytopenia frequently occurred, and it was the most important SAE. For anticipation of SAEs and its emergence time, we need to accumulate more experiences of GDP.